Australia: A NSW tribunal has given the green light for a potential trial of a COVID-19 treatment on critically ill patients who are unable to consent, concluding the trial was in their best interests and involved a low risk.
The trial would involve STC3141, a drug developed by researchers at the Australian National University.GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control
GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control
May 6, 2020, Hong Kong — China Grand Pharmaceutical and Healthcare Holdings Limited (“GP (HK)” or the “Company”, together with its subsidiaries, the “Group”, stock code: 00512) is pleased to announce that, Grand Medical Pty Ltd, a wholly-owned subsidiary of the Group and a new drug research center established in Australia, is developing a world-wide innovative drug STC3141 for the treatment of sepsis.
Griffith University Australia : A major scientific and commercialisation highlight in 2019 was the signing of a landmark multi-million deal between the Institute for Glycomics and Grand Medical Pty Ltd, a subsidiary
of China Grand Pharma, to develop a new drug to fight human
parainfluenza virus (hPIV). For over a decade we have built strong
scientific expertise and a robust suite of potent lead drug-like
molecules against hPIV. This significant co-development program
with Grand Medical Pty Ltd, to deliver a new drug to treat hPIV,
represents a significant milestone for the Institute.
History of the company Incorporated in Bermuda
|Principal Bankers:||The Hongkong and Shanghai Banking Corporation Limited|
Bank of China
China Merchants Banks
In 2005 Outwit Investments Limited become the main shareholder and that company is primarily controlled by Hu Kaijun is president of China Grand Enterprises, a formerly state-owned enterprise now active in healthcare, real estate and financial services.
|Outwit Investments Limited||Hu Kaijun||167167.11||49.49|
Completed a joint venture with Huangshi Feiyun Pharmaceutical Co., Ltd. was founded in 1992. The company’s line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparations for human or veterinary use.
2015 – 73% Joint venture with German company Cardionovum GmbH is a medical products company. The Company develops and commercializes medical therapies designed to improve upon current patient treatment standards for drug-eluting stents and drug-eluting balloons to treat coronary and peripheral artery disease.
2017 – aquired shares of Conavi Medical Inc a cardiac imaging company and establish a joint venture
2019 – Entered in to an exclusive agreement with Glenmark Specialty S.A. from Switzerland with the only financial contact being a William Lee who helped invent – (But not sure if it is the same William Lee)
Process for making 2-amino-2-imidazoline, guanidine and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives
Patent number: 6066740
Abstract: The present invention provides a process for making 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydroyrimidine derivatives by preparing the corresponding activated 2-thio-subsituted-2-derivative in a two-step, one-pot procedure and by further reacting yields this isolated derivative with the appropriate amine or its salts in the presence of a proton source. The present process allows for the preparation of 2-amino-2-imidazolines, quanidines, and 2-amino-3,4,5,6-tetrahydropyrimidines under reaction conditions that eliminate the need for lengthy, costly, or multiple low yielding steps, and highly toxic reactants. This process allows for improved yields and product purity and provides additional synthetic flexibility.
Filed: November 25, 1997
Date of Patent: May 23, 2000
Assignee: The Procter & Gamble Company
Inventors: Michael Selden Godlewski, Sean Rees Klopfenstein, Sreenivasa Reddy Mundla, William Lee Seibel, Randy Stuart Muth
2019 – purchase 44% of oncosec.com that researches cancer immunity.
2019 – Entered in to licensing and co-development for treatment of – Human parainfluenza viruses (HPIVs) are the viruses that cause human parainfluenza. HPIVs are a paraphyletic group of four distinct single-stranded RNA viruses belonging to the Paramyxoviridae family. These viruses are closely associated with both human and veterinary disease.
The Board of China Grand Pharmaceutical and Healthcare Holdings Limited, commented: “On March 22 2020, the Group obtained rights of technical and intellectual property for the world-wide first developed drug APAD from Chongqing AnTi New Bio-technology Limited, which is used for the treatment of Sepsis. The approval for phase Ib clinical research on sepsis may facilitate the development of drug STC3141 for sepsis in line with the expected timetable. APAD and STC3141 will jointly boost the development of the Group in the treatment of Sepsis and achieve synergies to enhance the Group’s innovative competitiveness in the field of emergency medicine. And the approval for kick-off the phase II clinical research of COVID-10 ARDS may push it to be one of the new candidate in the COVID-19 ARDS treatment aspect with fastest progress around the world. This may speed up the global development of this product against multi-indications, provide solutions to more patients and make contribution towards global epidemic prevention and control. In the future, the Group will continue to focus on enriching high-quality products and enhancing the competitiveness of the Group’s innovative products. Furthermore, the Group will emphasize on corporate social responsibility to reward shareholders and society with good financial performance and corporate image.”
Let’s quickly confirm that the investor is the Chinese communist party – Outwit Investments Limited
Here is the complex financial structure of what the Chinese have setup. Notice they even call the parent company “Outwit Investments Limited”, again showing their predatory practices and desire to outwit everyone else and be number one at the expense of everyone else instead of being a good global player.
Outwit Investments Limited, a company incorporated in the British Virgin Islands with limited liability, has an ownership of 40% by Mr. Hu and 60% by Grand Investment.
Grand Investment is a company incorporated in Hong Kong with limited liability which is wholly owned by China Grand, which in turn is controlled and ultimately and beneficially owned by Mr Hu.
Mr. Hu was China’s Communist Party chief for five years and state president for four. Mr. Hu was Party Committee Secretary for Guizhou province and the Tibet Autonomous Region and we all know the slaughter and what happened in Tibet. Hu is a hard-core communist who “reintroduced state control in some sectors of the economy” that were relaxed by previous communist administrations. In other words Mr. Hu was involved in cracking down on free markets, seizing wealth, and putting entire sectors back under strict communist government control.